Fieux Maxime, Castro Bruna R, Jang Sophie S, Yan Carol H, Patel Zara M
Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de Chirurgie Cervico-Faciale, Pierre Bénite Cedex F-69495, Université de Lyon, Lyon, France.
Int Forum Allergy Rhinol. 2025 Apr;15(4):420-427. doi: 10.1002/alr.23505. Epub 2024 Dec 30.
Platelet-rich plasma (PRP) injections have previously been shown to benefit coronavirus disease 2019 (COVID-19)-induced smell loss. It is unknown if that benefit is stable over time. The aim of this study was to assess outcomes at 1-year post-intervention.
Prospective cohort study. Sixteen patients (10 PRP and six placebo) from the original PRP randomized placebo-controlled clinical trial, and a further 16 patients from smell clinic who were a year out from initial treatment (six PRP patients and 10 non-PRP) were enrolled. University of Pennsylvania Smell Identification Tests (UPSITs) and visual analog scale (VAS) subjective scores were compared to initial scores.
There was no difference between groups with respect to age, gender, race, duration of smell loss prior to intervention, smoking or diabetes status, Charlson comorbidity index, presence of phantosmia or parosmia, or baseline UPSIT score. The PRP group had a significantly higher change in UPSIT score at 1 year (p = 0.001), a higher number of patients who met the minimal clinically important difference for the UPSIT (87.5% vs. 31.2%, p = 0.004), and a significantly greater change in VAS at 1 year (p = 0.001), compared to those who did not receive injections. On multivariate logistic regression analysis, no factors appeared to have a significant effect on these findings.
PRP injections into the olfactory cleft now have long-term data suggesting benefit in both subjective and psychophysical measures of smell, and improvements in both realms at 1 year are significantly higher than in those who do not receive the injections.
此前已证明，注射富含血小板血浆（PRP）对2019冠状病毒病（COVID-19）导致的嗅觉丧失有益。尚不清楚这种益处是否随时间稳定存在。本研究的目的是评估干预后1年的结果。
前瞻性队列研究。纳入了原始PRP随机安慰剂对照临床试验中的16名患者（10名接受PRP治疗，6名接受安慰剂治疗），以及另外16名来自嗅觉门诊且距离初始治疗已过去一年的患者（6名接受PRP治疗的患者和10名未接受PRP治疗的患者）。将宾夕法尼亚大学嗅觉识别测试（UPSIT）和视觉模拟量表（VAS）主观评分与初始评分进行比较。
在年龄、性别、种族、干预前嗅觉丧失持续时间、吸烟或糖尿病状况、查尔森合并症指数、存在嗅觉幻觉或嗅觉倒错，或基线UPSIT评分方面，各组之间没有差异。与未接受注射的患者相比，PRP组在1年时UPSIT评分的变化显著更高（p = 0.001），达到UPSIT最小临床重要差异的患者数量更多（87.5%对31.2%，p = 0.004），且在1年时VAS的变化显著更大（p = 0.001）。在多因素逻辑回归分析中，没有因素似乎对这些结果有显著影响。
现在有长期数据表明，向嗅裂注射PRP对嗅觉的主观和心理物理学测量均有益，且在这两个方面1年时的改善均显著高于未接受注射的患者。
